PRMT1: A Versatile Regulator of Gene Expression and Potential Drug Target

Target Name: PRMT1

NCBI ID: G3276

PRMT1

PRMT1: A Versatile Regulator of Gene Expression and Potential Drug Target

PRMT1 (Protein Arginine N-Methyltransferase 1) is a gene that encodes a protein that plays a crucial role in the regulation of gene expression in cells. The protein is expressed in most tissues and cells of the body, and it is involved in the transfer of arginine residues to the 3'-end of target genes.

PRMT1 is highly conserved across various species, and it has been implicated in various cellular processes, including cell signaling, DNA replication, and repair, and cell survival. The protein has also been linked to various diseases, including cancer, neurodegenerative diseases, and developmental disorders.

One of the key functions of PRMT1 is its role in epigenetic regulation. Epigenetic modification is a process by which the structure of a gene's DNA is modified without changing its sequence. This modification can include the addition or removal of methyl groups, which are important for the regulation of gene expression. PRMT1 is involved in the transfer of arginine residues to the 3'-end of target genes, which is a critical step in the epigenetic modification process.

In addition to its role in epigenetic regulation, PRMT1 is also involved in the regulation of protein translation. Protein translation is the process by which RNA molecules are translated into proteins. PRMT1 has been shown to play a role in the regulation of protein translation by binding to specific protein targets and modifying their stability.

PRMT1 has also been linked to various diseases, including cancer. In cancer, the regulation of gene expression is often disrupted, and this can lead to the development of malignant behaviors. PRMT1 has been shown to play a role in the regulation of gene expression in cancer cells, and it has been proposed as a potential drug target or biomarker.

One of the potential drug targets for PRMT1 is the inhibition of its activity. This can be achieved through various mechanisms, including the inhibition of its catalytic activity, the inhibition of its transactivation, or the inhibition of its stability.

Another potential approach to target PRMT1 is the inhibition of its target genes. This can be achieved through various mechanisms, including the inhibition of the translation of its target genes, the inhibition of its epigenetic modifying activity, or the inhibition of its interaction with its co-factors.

In addition to its potential as a drug target or biomarker, PRMT1 is also a potential biomarker for various diseases. For example, high levels of PRMT1 have been observed in certain types of cancer, and these levels can be used as a diagnostic or prognostic marker.

Overall, PRMT1 is a protein that plays a crucial role in the regulation of gene expression and has been implicated in various cellular processes. Its potential as a drug target or biomarker makes it an attractive target for further research and development in the field of cancer and other diseases.

Protein Name: Protein Arginine Methyltransferase 1

Functions: Arginine methyltransferase that methylates (mono and asymmetric dimethylation) the guanidino nitrogens of arginyl residues present in proteins such as ESR1, histone H2, H3 and H4, FMR1, ILF3, HNRNPA1, HNRNPD, NFATC2IP, SUPT5H, TAF15, EWS, HABP4, SERBP1, RBM15, FOXO1, CHTOP and MAP3K5/ASK1 (PubMed:10749851, PubMed:16879614, PubMed:26876602, PubMed:22095282, PubMed:26575292, PubMed:18951090, PubMed:25284789, PubMed:30765518). Constitutes the main enzyme that mediates monomethylation and asymmetric dimethylation of histone H4 'Arg-4' (H4R3me1 and H4R3me2a, respectively), a specific tag for epigenetic transcriptional activation. May be involved in the regulation of TAF15 transcriptional activity, act as an activator of estrogen receptor (ER)-mediated transactivation, play a key role in neurite outgrowth and act as a negative regulator of megakaryocytic differentiation, by modulating p38 MAPK pathway. Methylates RBM15, promoting ubiquitination and degradation of RBM15 (PubMed:26575292). Methylates FOXO1 and retains it in the nucleus increasing its transcriptional activity (PubMed:18951090). Methylates CHTOP and this methylation is critical for its 5-hydroxymethylcytosine (5hmC)-binding activity (PubMed:25284789). Methylates MAP3K5/ASK1 at 'Arg-78' and 'Arg-80' which promotes association of MAP3K5 with thioredoxin and negatively regulates MAP3K5 association with TRAF2, inhibiting MAP3K5 stimulation and MAP3K5-induced activation of JNK (PubMed:22095282). Methylates H4R3 in genes involved in glioblastomagenesis in a CHTOP- and/or TET1-dependent manner (PubMed:25284789). Plays a role in regulating alternative splicing in the heart (By similarity)

The "PRMT1 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about PRMT1 comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets